Skip to content
Screener

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.32B+25.8%
Eli Lilly logo
Eli LillyLLY
$31.89B+83.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$171.67B+3.8%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
AbbVie logo
AbbVieABBV
-$17.87B-87.6%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
-$532.62M-93.3%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 20252,9312,931
Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5049
Additional paid-in capital705,196657,561
Accumulated other comprehensive income (loss)(480)546
Accumulated deficit(220,977)(189,157)
Total stockholders’ equity486,720471,930
Total liabilities and stockholders’ equity$504,480$488,617

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s retained earnings?
Oruka Therapeutics, Inc. (ORKA) reported retained earnings of -$220.98M in Q1 2026.
How has Oruka Therapeutics, Inc.'s retained earnings changed year-over-year?
Oruka Therapeutics, Inc.'s retained earnings decreased by 111.0% year-over-year, from -$104.72M to -$220.98M.
What is the long-term trend for Oruka Therapeutics, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s retained earnings has grown at a 4.2% compound annual growth rate (CAGR), from -$154.15M to -$189.16M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Oruka Therapeutics, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude